120+ Insightful Sessions

Medicine is just the beginning

    • Keynotes
    • Commercial
    • Digital
    • Patients
    • Data & RWE
    • Market Access
    • Medical Affairs
    • Keynotes
    • Commercial
    • Digital
    • Patients
    • Data & RWE
Medicine is just the beginning: we are now in the health innovation industry
  • Pharma is dead, long live pharma. How a prioritisation of patient outcomes instigates a profound evolution of who and what our industry is.
  • How and why it is essential to move from a science-driven organisation to a true data-driven organisation
    • Keynotes
    • Commercial
    • Patients
To care is to become a pioneer
  • Why scientific innovation needs to be applied to caregiving in the industry if we are to evolve
  • How equity in your workforce and greater employee-centricity translates externally to real patient centricity
    • Keynotes
    • Patients
    • Commercial
Prevention is better than cure at Janssen’s WWDA (World Without Disease Accelerator)
  • Why new treatments including gene and cell therapies are building on pharma’s historic successes and are priority investments today
  • Move from sick care to health care by moving health ecosystems upstream and improved personalisation
    • Keynotes
    • Commercial
    • Digital
Your agility ability: why adopting more iterative and experimental innovation techniques need a new type of learning culture
  • Why your revenue-focused objectives will fail in an entrepreneurial environment
  • Ways you can create faster, more experimental innovation without sacrificing safety and reliability
    • Keynotes
    • Commercial
    • Digital
    • Patients
    • Medical Affairs
    • Data & RWE
    • Market Access
The Start-up elevator pitches
  • 6 hand-picked startups each have just three minutes to demonstrate disruption and win your support
  • Understand how a strong vision makes the lack of resources only a temporary setback
    • Keynotes
    • Market Access
    • Data & RWE
Value-based contracting now, not tomorrow
  • Why VBC is the inevitable solution for our industry
  • How to raise the ambitions for your Real-World Insights
    • Keynotes
    • Patients
    • Commercial
We fight for the patient – and the patient fights for us
  • How the smartest companies are able to go beyond empowerment, beyond advocacy and work with patients for sustained access in a virtuous circle
  • Why your goal must be to have the most comprehensive patient insights if you are ever going to gain trusted partner status
    • Keynotes
    • Patients
    • Commercial
    • Digital
    • Medical Affairs
The Authenticity Factor: how CMOs can pioneer rapid-reaction strategy based on continuous data input
  • Hear the argument for re-centralisation of medical teams in order to create a core of medical expertise
  • Determine to what degree medical and commercial must align – and how to empower them with high-grade datasets
    • Keynotes
    • Market Access
    • Data & RWE
Regulation Revolution: how the FDA and EMA are enabling a new era of innovation
  • How patients are becoming the driver of regulatory evolution through incorporating their experience into our benefit-risk assessments.
  • Understand the imminent and significant changes that regulators and payers are devising
    • Keynotes
    • Digital
    • Commercial
    • Patients
    • Market Access
How the Otsuka-Proteus collaboration has invented digital therapeutics as a new drug category
  • Witness how a shared commitment to address non-adherence in mental illness has created an edible, microscopic communication platform, approved by the FDA
  • How the connection of hardware (as a medicine) and software has resulted in new product categories with a range of capabilities
    • Keynotes
    • Commercial
    • Digital
    • Patients
Exceed the expectations of increasing consumerization
  • Where we need to move from B2B to B2C and what the finest in FMCG and Financial Services are doing to remodel
  • Move patients from ‘empowered’ to ‘being in charge’ by investing in literacy and enabling them as adjudicators within the access equation.
    • Keynotes
Keynote Speakers

Brent Saunders

CEO

Allergan

Kris Sterkens

Company Groups Chairman, Europe, Middle East and Africa

Janssen

David Meek

CEO

Ipsen

Belén Garijo

Member of the Executive Board, CEO Healthcare

Merck Group

Zach Weinberg

Co-Founder

Flatiron Health

Gitte Aabo

President & CEO

LEO Pharma

Mark Mallon

Executive Vice President, Global Product and Portfolio Strategy

AstraZeneca

Steven Hildemann

SVP, Patient Safety and Chief Medical Officer

Merck Group

Bharat Tewarie

EVP & Chief Marketing Officer

UCB

Ryan Olohan

Managing Director, Healthcare

Google

Marc Princen

Executive Vice President and President, International Business

Allergan

Colin Sims

Senior Vice President, Head, Transversal Corporate Strategy

Sanofi

Kabir Nath

President and CEO

Otsuka North America

Andrew Thompson

Co-Founder and CEO

Proteus Digital Health

Catalyse trust in RWE

    • Data & RWE
    • Market Access
    • Data & RWE
    • Market Access
Stakeholder Panel: Understand the acceptability of RWE across global regulatory decision-making
  • Explore the evolving role of RWE in the evidence lifecycle, quality expectations and the possibility of regulatory grade RWE
  • Discuss the impact of regulatory policies, such as 21st Century Cures Act, on the global adoption of RWD into R&D and Access framework

Khair ElZarrad

Deputy Director, Office of Medical Policy

FDA

Giuseppe Rosano

Member CVWP, European Medicines Agency, Consultant Cardiologist, Agenzia Italiana del Farmaco

EMA

Christoph von der Goltz

Senior Director, Head of HEOR & RWE

Lundbeck

    • Data & RWE
    • Market Access
Drive the adoption of RWE
  • Explore key driving forces preventing increased adoption of RWE from a force field perspective
  • Discuss approaches to further build a robust European healthcare data-scape

David Leather

Medical Vice President, Respiratory Franchise

GSK

    • Data & RWE
Federated & harmonised real world research in Europe – 2020 and beyond
  • Discuss key challenges and objectives from key European projects (EMIF & EHDEN) in creating a sustainable harmonised EU data ecosystem
  • Explore current and predicted impact IMI European Health Data Network (EHDEN) now underway

Nigel Hughes

Scientific Director

Janssen

Create your data symphony

    • Data & RWE
    • Medical Affairs
    • Market Access
    • Data & RWE
    • Medical Affairs
    • Market Access
Advance data generation by unlocking the value of academic collaboration
  • Ensure full transparency and compliance to maintain ethics and enhance pharma’s external image
  • Understand the full potential of using academic partners in comparison to traditional CROs

Thomas D'Hooghe

Vice President and Head, Global Medical Affairs Fertility

Merck Group

    • Data & RWE
    • Medical Affairs
    • Market Access
Hone your RWE generation strategy in Specialty and Rare Diseases
  • Use RWE to define clinical trial endpoints and meet Market Access goals in rare diseases
  • Understand the multiple channels and high quality data sources available and usable

Dirk Vander Mijnsbrugge

VP, Medical Affairs Lead International Developed Markets

Pfizer

    • Data & RWE
    • Medical Affairs
Machine learning and emerging analytical approaches for Regulatory and Safety RWE
  • Lessons learnt in building internal capacity to accept new technology through training and partnerships
  • How to take advantage of new capabilities to combine, use and extract data while staying compliant and ensuring appropriate impact"

Andrew Bate

Senior Director, Analytics Team Lead, Epidemiology

Pfizer

Reimagine R&D with RWE

    • Data & RWE
    • Medical Affairs
    • Data & RWE
    • Medical Affairs
Modernise the development paradigm with RWE
  • Explore how Boehringer are using RWE to complement data from clinical trials with new levels of patient population understanding
  • Enhance development efforts with easily accessible and communicable RWD platforms

Amanda Golembesky

Head of Real World Evidence Analytics Center of Excellence

Boehringer Ingelheim

    • Data & RWE
    • Medical Affairs
Understand how to prove real-world effectiveness pre-launch
  • Case Study: Explore how phase II of the IMI GetReal programme is developing industry-wide standards and methodologies to accelerate adoption of RWE
  • Discuss how to incorporate RWE into the traditional R&D framework and tools available now to enhance operational efforts

Páll Jónsson

Associate Director Science Policy and Research

NICE

Rob Thwaites

Former Senior Director, Strategy, Global Outcomes Research (GOR) and Head, GI, GOR

Takeda

Wim Goettsch

Special Advisor HTA, ZINL; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht

ZINL

RWE driven Market Access

    • Data & RWE
    • Market Access
    • Patients
    • Data & RWE
    • Market Access
Understand how RWE assessment fits into different HTA assessment methodologies across Europe
  • Bring it home: use local affiliates to feed into international RWE and access planning
  • Compare and contrast the range of HTA evidence hierarchies across Europe

Wim Goettsch

Special Advisor HTA, ZINL; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht

ZINL

    • Data & RWE
    • Market Access
    • Patients
Smarter use of PROs to turn patient value into payer value
  • How to move beyond clinical measures and successfully capture what truly matters to patients to secure access

Daniel Jackson

Global Head, Market Access Solutions and Strategy

UCB

    • Data & RWE
    • Market Access
Value-based contracting: use best-in-class predictive analytics
  • Forecast commercial performance by establishing value benchmarks and data quality from the outset

Market Access stakeholder harmony

    • Market Access
    • Medical Affairs
    • Market Access
    • Medical Affairs
Panel: How to work more openly with HTAs to improve patient care and match medical innovation
  • Discuss the changing needs for value assessment as levels of effectiveness increase
  • How to foster more transparent partnership with government bodies

Martin Price

Vice President, Health Economics, Market Access & Reimbursement

Janssen

Adam Kundzewicz

Global Head of Strategic Market Access Initiatives

Boehringer Ingelheim

Stefan Holmstrom

HTA Strategy and PRO Excellence, Head

Astellas

    • Market Access
Panel: Drive market access innovation in a risk averse environment
  • Explore the next steps in creating an environment capable of successfully enacting more outcomes-based agreements
  • Strengthen stakeholder alignment with understanding of the groundwork capabilities needed for data needs

Ulf Staginnus

Senior Vice President, Head Global Market Access & Pricing

Ipsen

Anant Murthy

VP, Market Access, Pricing & Policy, General Manager BE/NL/LU

Alynlyam

Drive Access innovation

    • Market Access
    • Patients
    • Market Access
Pricing innovation in the face of CAR-T and gene therapy
  • Explore how to implement appropriate outcomes-based pricing models to match treatment innovation
  • Understand the new needs of payers given the increasing levels of complexity in timelines and outcomes

Martin Price

Vice President, Health Economics, Market Access & Reimbursement

Janssen

    • Market Access
    • Patients
Accelerate patient access to new treatments – NICE Patient Pathways
  • Discuss pharma’s role in ensuring patient access and care are optimised for newly approved treatments
  • Explore NICE’s new initiative enhancing the clinical/patient guidance for treatment at the point of approval

Gillian Leng

Deputy Chief Executive Officer

NICE

Commercial Focused Roundtables

    • Roundtables
    • Commercial
    • Digital
    • Roundtables
    • Commercial
    • Digital
  1. Are nudging strategies the solution to make communication strategies more effective?
  2. Understand how pharma needs to react to rising benchmarks are essential in order to keep up a positive customer experience
  3. Enable reps to deliver more immersive education with VR tools
  4. Beyond education: become a source of inspiration for HCPs
  5. Improve personalisation with a 360-degree view of your customer
  6. Remove complexity with smarter KAM and MSL coordination
  7. Patient perspectives on the good, the bad and the ugly of service design

Roundtable facilitators include:

Inge Bliestle

Director, Commercial Operations

Actelion

Carsten Grandke

Lead, Center of Excellence Multichannel Marketing

Teva

Patrice Baudry

Executive Vice President G3M

LEO Pharma

Anita Natzkova

Global Insights Established Pharmaceuticals

Abbott

Rami Virtanen

Global Channel Lead

GSK

Design Thinking Workshop

    • Roundtables
    • Commercial
    • Digital
    • Roundtables
    • Commercial
    • Digital

Accelerate innovation by addressing patient and company challenges with design thinking

  1. Learn how aspects of design thinking can be applied to generate solutions and solve even the most complex problems in the healthcare environment,
  2. Think beyond digital, ensuring your organisation utilises new technology and ways of thinking to enhance the patient journey.
  3. Envisage how other industries and companies have embedded design thinking within their organisation, which allows for continuous feedback and improvements to products and services

Curated and led by:

Gregory Miller

Vice President and Global Head Innovation Accelerator CoE

UCB

Medical & Commercial: Field Force Effectiveness Taskforce Roundtables

    • Roundtables
    • Commercial
    • Medical Affairs
    • Roundtables
    • Commercial
    • Medical Affairs
  1. Explore the evolution of pharma’s medical and commercial field force in a fast-changing external environment
  2. In an hour-long interactive session hosted by field force leaders understand emerging capability requirements, measure effectiveness and ensure successful interactions

Roundtable facilitators include:

Dirk Abeel

Global Head - Medical Field Effectiveness

Nestle

Heather Moses

Head of Medical Affairs

Roche

Walter Sheloff

Customer Facing Medical Effectiveness Lead

Pfizer

Mauricio Silva de Lima

VP, Medical Europe

Roche

Real-World Evidence Focused Roundtables

    • Roundtables
    • Data & RWE
    • Roundtables
    • Data & RWE
  1. Design your internal RWE function: capability requirements, future proofing, ownership, investment needed
  2. The impact of GDPR: discuss the impact existing and future privacy regulations/policies may
  3. Meet RWE regulatory standards: which internal functions should take leadership/ensure relative quality in emerging area
  4. Tapping Academic collaboration: explore the full potential of academic partnership for data generation
  5. Changing the public perception: pharma’s role in educating and improving negative public attitudes to health data use
  6. RWE in clinical trials: how best to bring big data into the development process
  7. The pragmatic solution: why defining the right question for pragmatic studies is key
  8. The future of data standardisation: explore existing and future European efforts to create a sustainable harmonised EU data ecosystem

Roundtable facilitators include:

Nigel Hughes

Scientific Director

Janssen

Thomas D'Hooghe

Vice President and Head, Global Medical Affairs Fertility

Merck Group

Market Access Focused Roundtables

    • Roundtables
    • Market Access
    • Roundtables
    • Market Access
  1. Patient + value = payer value: how to articulate new patient journey understanding into a language payers understand
  2. Monopoly vs. Monopsony: risks and opportunities for companies and payers/health systems in joint value assessments and negotiations in Europe
  3. Stronger value-based contracting: discuss key challenges and stumbling blocks in payer negotiations for value-based agreements
  4. Italy’s outcomes-based experience: deep dive into the challenges and key learnings from the early movers into outcomes-based agreements in Europe
  5. Master your ePRO/ePREM approach: discuss how to unlock more value-based access with greater patient outcome understanding
  6. Market Access 101: learn the basics on the European Market Access landscape and internal pharma functionality
  7. Internal access alignment: discuss how best to pool capabilities and define Market Access responsibilities
  8. Globalisation vs regionalisation: understand how you can meet local market needs through different submission adaptation approaches

Roundtable facilitators include:

Agathe le Lay

Director, Head of HEOR

Lundbeck

Thomas Temme

Head of Value Demonstration & Access & Public Affairs Germany, Austria & Switzerland

Shire

Lara Pippo

Head of Italy Market Access

CSL

Redefine Medical’s Value

    • Medical Affairs
    • Medical Affairs
Medical as leader: discuss how a centralised medical function can improve dynamics with HCPs
  • See whether a concentrated medical HQ team can equip field teams with the skills and capabilities for more effective interactions
  • Discuss the strategic considerations in maintaining a balance of global and regional approaches

Christopher Keenan

Head, Worldwide Medical Customer Engagement, Medical Capabilities

BMS

José Antonio Burón Vidal

Vice President EMEA Medical Affairs

Johnson & Johnson

    • Medical Affairs
The evolution of Medical Affairs role in the Medicines Development Process
  • Make development patient-centric and value-oriented with a more strategic approach using Medical leadership
  • Understand the structural and capability requirements for involvement in the complete life cycle from idea generation on

Pol Vandenbroucke

SVP, Chief Development Officer

Pfizer Essential Health

    • Medical Affairs
Beyond education: become a source of inspiration for HCPs
  • Give HCPs revealing insights about patient populations and enable them to provide real service to patients

Mauricio Silva de Lima

VP, Medical Europe

Roche

Enhance Medical Interactions with Digital Excellence

    • Medical Affairs
    • Digital
    • Medical Affairs
    • Digital
Use digital as a driver for Medical authenticity and authority
  • Let Medical Affairs be Medical Affairs: Increase effectiveness and efficiencies using digital tools to enhance scientific exchange, medical education and medical programs
  • Explore emerging avenues of high quality data gathering with digital tools

Cesar Sanz Rodriquez

Associate Vice President, Medical Affairs Lead EURAM

MSD

    • Digital
    • Medical Affairs
The next-generation digital congress experience 
  • Amplify the value of your congress campaigns with innovative digital content and communications
  • Use relevant, real-time content to engage with your key customers and stakeholders to improve their congress experience

Felix Jackson

Founder and Medical Director

MedDigital

2019s Commercial Imperatives

    • Medical Affairs
    • Digital
    • Commercial
    • Medical Affairs
    • Commercial
Panel: The rep of tomorrow, today
  • Fast-track a new paradigm for your sales reps and MSLs
  • Define the balance of responsibilities and objectives throughout your whole field team

Dirk Abeel

Global Head - Medical Field Effectiveness

Nestle

Walter Sheloff

Customer Facing Medical Effectiveness Lead

Pfizer

Inge Bliestle

Director, Commercial Operations

Actelion

    • Medical Affairs
    • Commercial
Field Force Effectiveness Taskforce
  • Explore the evolution of pharma’s medical and commercial field force in a fast-changing external environment
  • In an hour-long interactive session hosted by field force leaders understand emerging capability requirements, measure effectiveness and ensure successful interactions

Heather Moses

Head of Medical Affairs

Roche

Walter Sheloff

Customer Facing Medical Effectiveness Lead

Pfizer

Dirk Abeel

Global Head - Medical Field Effectiveness

Nestle

Mauricio Silva de Lima

VP, Medical Europe

Roche

    • Digital
    • Commercial
Working towards 'better': How Google is making genuine helathcare breakthroughs
  • Successfully implement the change needed to constantly improve productivity and leverage data to make smarter decisions

Ryan Olohan

Managing Director, Healthcare

Google

    • Digital
    • Commercial
Being disruptive from within- The LEO Innovation Lab story
  • Hear how LEO Innovation Lab ensure agility and how they can continuously drive innovation
  • Find out how they use patient insights to leverage innovative new solutions in AI, assistant tools and machine learning.

John Zibert

Chief Medical Officer

LEO Innovation Lab

Be more than just a partner

    • Digital
    • Commercial
    • Digital
    • Commercial
An end-to-end view to your customer suite
  • Adopt a multi-customer model: Physicians, Payers, Policy Makers and Patients. Integrated multi-customer strategies are the way forward.

Ana Cespedes

Chief Operating Officer

IAVI

    • Digital
    • Commercial
The digitally mature sales function: how you can transform sales reps into catalysts
  • How real digital transformation will be dependent on capabilities of your customer-facing teams

Naji Gehchan

Chief Marketing Officer & Bio Medicines Leader - France

Eli Lilly

    • Commercial
Sandoz Case Study: Commercial Excellence: as strong as the weakest link
  • Understand the end-to-end process and understand that customer centricity as the key lighthouse and everything you need to do to ensure you meet the expected customer experience.

Gabriel Morelli

Global Head of Commercial Excellence

Sandoz International

    • Commercial
Customer Experience: how to design an intentional customer journey that resonates at every step
  • Plan the journey and action you want your customers to take and find the moments that you can move the needle

Luis Magarzo Bello

Commercial Excellence Head

Mylan

Genuine Patient Centricity through collaboration

    • Patients
    • Commercial
    • Market Access
    • Patients
From competitors to collaborators - form alliances in the interest of the patient
  • Stop creating your own platforms - co-create the one platform that patients admire

Carole Sian Scrafton

Patient Advocate

    • Patients
    • Commercial
    • Market Access
Shape the business landscape
  • Learn how anticipation of policy changes and proactive engagement on advocacy and policy shaping can be a critical source of competitive advantage.

Lynn Taylor

SVP, Global Healthcare Government & Public Affairs

Merck Group

    • Patients
    • Commercial
How Takeda has implemented the patient comes first approach- and the benefits received
  • Ways your organisation can gain maximum patient insights for multiple applications without losing efficiency
  • Ways to deep understanding of patient perspectives and leveraging insights for multiple applications without losing focus

Gundula Schnidewind

Managing Director, Belgium

Takeda

    • Patients
    • Commercial
Establishing true patient outcomes, starting with the patient right from the R&D process
  • Focusing on patient outcomes when designing ‘pharma plus digital’ products
  • Building a patient focused cross-functional agile team to launch a product

Panos Papakonstantinou

Musculoskeletal Mobility Solutions Commercial Director

Novartis

Support Patients from start to finish

    • Patients
    • Patients
Start with the service to go beyond just 'beyond the pill'
  • Understand how true value can be translated from the patient rather than from the medicine or treatment regimen
  • Understand how Merck has implemented a cross functional patient culture through it’s pharma sector

Steven Hildemann

SVP, Patient Safety and Chief Medical Officer

Merck Group

    • Patients
Real advocacy - how to become your patient organisation's number one partner
  • Innovate at the cutting edge of patient communication to generate fans, not just advocates

David Montgomery

Vice President, Global Science Exchange

Pfizer Oncology

Redefine your business

    • Digital
    • Patients
    • Commercial
    • Digital
    • Commercial
Achieve personalization through Omni-channel, longitudinal & behavioral analysis.
  • Establish an Omni-channel customer view, understand customer decision journeys
  • Observe customer behaviors and gather insights over short campaign iterations

Philippe Kirby

Digital Capabilites and Marketing Lead

MSD

    • Patients
    • Digital
AbbVie case study: Crush Your FOMO – empowering a nation to take control of its health
  • Hear how AbbVie is collaborating with experts from outside the health industry in a bold preventative health move. By putting open-data at the forefront, AbbVie will explore the value of leveraging real-life, data-driven insights to further understand complex human behaviour, in order to ultimately help build a more sustainable NHS.

Gwenan White

UK Director of Communications and Patient Relations

Abbvie

    • Commercial
Dare to Dare: Redefine your customer approach and get ready for transformation
  • Change your perspective. Engage with patients as the key decision makers they’re becoming, and empower them to make educated decisions about their own health.
  • Go deep to understand the patient journey and core customer needs. Do it well, and the insights can reveal hidden value pools, and possibly force you to change your company strategy
  • Meet the needs of your customers by applying relevant digital tools. Implement by applying a start-up way of working, and it will be rocket fuel for your strategy.

Christina Molt Wengel

Senior Vice President and Head of Global Marketing

ALK Pharmaceuticals

    • Digital
    • Commercial
Streamlining of customer experience with an omnichannel approach
  • Envision how an industry leading company has created a truly integrated omni-channel offering
  • Equip different departments to begin the omni-channel transition and ensure the required capabilities are in place
  • Tailor your marketing strategy to ensure alignment between various platforms to ensure a seamless, consistent and effortless user experience

Florent Edouard

SVP, Global Head of Commercial Excellence and Customer Engagement

Grünenthal Group

Philippe Kirby

Digital Capabilites and Marketing Lead

MSD

Patient Experience for Patient Centricity

    • Patients
    • Commercial
    • Patients
    • Commercial
Convince skeptics and prove the commercial value of a patient-centric approach
  • Obtain senior-level support for patient initiatives by linking efforts to outcomes

Simon Eade

Head Global Commercial Strategy

Actelion

    • Patients
    • Commercial
You can’t stand still- innovate into new areas of helping patients
  • Learn how Takeda Austria is taking steps to innovate STEM cell therapy and deliver much needed medicines to patients
  • Understand the implications needed to work together to deliver this 48-hour treatment and how Takeda is over coming these barriers

Kirsten Detrick

Head, Central Europe and Austria

Takeda

Gain traction and harness technology

    • Digital
    • Commercial
    • Digital
LEO Pharma – Growth Hacking their way to the top
  • Hear how LEO Pharma is hacking their way into better HCP engagement, the results and challenges
  • Understand not only the challenges of building the function and the business case for digital marketing

Kasper Jerlang

Head of Global Digital Marketing and Engagement

LEO Pharma

    • Digital
    • Commercial
The digitally mature sales function: how you can transform sales reps into catalysts
  • How real digital transformation will be dependent on capabilities of your customer-facing teams

Naji Gehchan

Chief Marketing Officer & Bio Medicines Leader - France

Eli Lilly

    • Digital
    • Commercial
The bottom-up approach to driving commercial digital transformation as a global team
  • Driving business change based on local business cases rather than a one-size-fits-all – with results
  • Practical applications of AI and automation to drive local business value
  • Working with all levels – from General Managers to Marketers - to change the ways of working
  • The hidden roadblocks and time saps in a true digital transformation

Lanre Ibitoye

Director , Head of Digital Platforms and Capabilites- Europe & International Markets

Teva

Davidek Herron

Head of Outbound Digital Channels, Europe and Interantional Markets

Teva

The Innovation Stage

    • Health Tech & Innovation
    • Data & RWE
    • Medical Affairs
    • Market Access
    • Digital
    • Patients
    • Commercial
    • Health Tech & Innovation
    • Data & RWE
    • Digital
Genomics and Blockchain: Decentralized genomic big data storage, sharing and analysis
  • Look into the future state of genomic data sharing and security as new technological advancements at the intersection of healthcare and information technology are developed.
  • Describe how blockchain technology can enable genomic data creation, ensure its security, and allow for its sharing
  • Discuss the future state of genomic research, genomic data security, genomic data standardization and data sharing between individuals and companies as whole genome sequencing costs continue to decrease.

Dennis Grishna

Co-Founder

Nebula Genomics

Kamal Obbad

Co-Founder

Nebula Genomics

    • Health Tech & Innovation
    • Data & RWE
The Digitome: The first digital representation of health and disease
  • Understand the Human Digitome Project: long-term vision for the platform, including opening it up so that anyone can proactively use it themselves, so that researchers will understand more about how diseases work, and how to cure them.
  • How AI is being used to look for patterns in the ways patients contract diseases and react to medication, to give doctors more information about people’s health
  • How blockchain enables patient-centric data

Michelle Longmire

CEO

Medable

    • Health Tech & Innovation
    • Medical Affairs
    • Commercial
How single-cell transcriptomics will redefine human diseases and unearth novel therapeutic avenues
  • Everything you need to know about The Human Cell Atlas, an ambitious project, funded by the Chan-Zuckerberg Institute and others, to map every cell in the human body and how this could impact how drugs are developed
  • Learn how the single revolution is rewriting our understanding of a human disease ranging from cancer to inflammatory conditions

Sam Behjati

Wellcome Trust Intermediate Clinical Fellow

Wellcome Sanger Institute

    • Health Tech & Innovation
    • Commercial
What commercial pharma needs to know about blockchain

Ben Taylor

CEO

LedgerDomain

    • Health Tech & Innovation
    • Digital
    • Commercial
The first biopharma company to be born in the cloud
  • Understand how Moderna Therapeutics has evolved as a truly digital biopharma organization and what this means for advancing drug candidates to clinical studies; increasing the agility of its research, development, and manufacturing processes; and achieveing results—such as personalized cancer vaccines—that would have been impossible even a few years ago.
  • Lessons learnt from their journey and their vision for the future of the company and what this means for the future pharma business model

Marcello Damiani

CDO

Moderna Therapeutics

    • Health Tech & Innovation
    • Patients
Training our immune system to prevent and cure chronic diseases.
  • Understand that the prevention and management of chronic diseases should focus not only on symptomatic patients but on individuals that do not yet have symptoms.
  • Discuss how this disease-prevention strategy profoundly impacts clinical development, marketing and distribution of products, and new payor models.
  • Appreciate how digital strategies that affect an individual’s behaviour towards lifestyle choices, can enhance adherence to treatment and positively affect clinical outcome

Oliver Siegel

CEO

AFFiRiS

    • Health Tech & Innovation
    • Patients
    • Digital
Liberate the scientists! How AI is propelling a drug discovery revolution
  • Why the pharmaceutical industry is failing in the innovation imperative
  • Understand how AI can increase the efficiency and increase the chance of success of drug discovery and transform drug discovery as we know it
  • See how this disruption is already happening and show how AI can impact the whole value chain

Jackie Hunter

Chief Executive, Clinical Programmes & Strategic Relationships

Benevolent Bio

    • Health Tech & Innovation
    • Digital
    • Patients
PANEL: Without the pill: How digital therapeutics can drive market access innovation and herald in a new era of shared value
  • Discuss how the current partnership model is floored and why we need to be partnering for new kinds of value
  • Find out how the leading organizations are partnering by focusing on the friction and pain points of care, and building value alliances with key stakeholders

David Van Sickle

CEO

Propeller Health

Matthew Bonam

Head of Intelligent Pharmaceuticals

AstraZeneca

    • Health Tech & Innovation
    • Market Access
Reimburse digital solutions - lessons learnt from Germany’s most successful reimbursement case study
  • Understand how Sonormed successfully gained market access for Germany’s first health product mobile app before it’s even been developed
  • Explore the payer negotiation process and hear feedback from reimbursement considerations shaping product development

Jörg Land

CEO

Sonormed

    • Health Tech & Innovation
    • Commercial
What commercial pharma needs to know about blockchain

Ben Taylor

CEO

LedgerDomain

Session SubHeading

    • Keynotes
  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator:

Steven Hildemann

SVP, Patient Safety and Chief Medical Officer

Merck Group

Ryan Olohan

Managing Director, Healthcare

Google

John Zibert

Chief Medical Officer

LEO Innovation Lab

Khair ElZarrad

Deputy Director, Office of Medical Policy

FDA

  • Wednesday 13th
  • 9.30-10.30am
    • Keynotes
    • Patient
Session title to go here written out like this

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

  • Identify the challenges pharma must overcome in this world of unpredictable social, economic and political change
  • Be the solution: redefine the role we play in the healthcare eco-system and come together to build the solutions that truly meet the need of patients and care givers
  • Recognise how other industries have been disrupted by unexpected competition and ensure pharma is prepared to face the challenges of tomorrow
  • Explore the world of healthcare from a higher perspective and ensure that we are at the core of the discussion on the shape of its future

Moderator:

Steven Hildemann

SVP, Patient Safety and Chief Medical Officer

Merck Group

Ryan Olohan

Managing Director, Healthcare

Google

John Zibert

Chief Medical Officer

LEO Innovation Lab

Khair ElZarrad

Deputy Director, Office of Medical Policy

FDA